TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
47.65
+1.03 (2.21%)
Jun 11, 2026, 3:26 PM EDT - Market open
TG Therapeutics Revenue
TG Therapeutics had revenue of $204.92M in the quarter ending March 31, 2026, with 69.56% growth. This brings the company's revenue in the last twelve months to $700.35M, up 81.26% year-over-year. In the year 2025, TG Therapeutics had annual revenue of $616.29M with 87.32% growth.
Revenue (ttm)
$700.35M
Revenue Growth
+81.26%
P/S Ratio
9.75
Revenue / Employee
$1,755,261
Employees
399
Market Cap
6.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 616.29M | 287.28M | 87.32% |
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | 152.00K | - | - |
| Dec 31, 2018 | 152.00K | - | - |
| Dec 31, 2017 | 152.00K | - | - |
| Dec 31, 2016 | 152.00K | -381.00 | -0.25% |
| Dec 31, 2015 | 152.38K | - | - |
| Dec 31, 2014 | 152.38K | - | - |
| Dec 31, 2013 | 152.38K | 133.33K | 699.98% |
| Dec 31, 2012 | 19.05K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.14B |
| PTC Therapeutics | 827.11M |
| Mirum Pharmaceuticals | 569.61M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Centessa Pharmaceuticals | 15.00M |
TGTX News
- 5 hours ago - TG Therapeutics Transcript: AGM 2026 - Transcripts
- 2 days ago - TG Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 days ago - TG Therapeutics announces Briumvi data, initiates clinical trial - TheFly
- 2 days ago - TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial - GlobeNewsWire
- 8 days ago - TG Therapeutics rises 10.6% - TheFly
- 8 days ago - TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 8 days ago - TG Therapeutics announces results from Briumvi trial - TheFly
- 8 days ago - TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy) - GlobeNewsWire